Director

Matthew L. Posard

Director·Halozyme Therapeutics, Inc.

About

Matthew L. Posard has served on the Halozyme Board of Directors since 2013, where he chairs the Nominating and Corporate Governance Committee and serves on the Audit Committee. He brings over 30 years of general management and commercialization experience in the biotechnology and diagnostics industry.

Mr. Posard is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016, and since 2017 has provided advisory services to CEOs of several emerging life sciences companies. From February 2017 to April 2018 he served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company, and from March 2015 to April 2016 as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015 he held various commercial and general management positions at Illumina, Inc., including senior executive positions overseeing Global Sales, Marketing, and serving as General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets. He has also held senior positions at Biosite, Inc. and Gen-Probe, Inc.

Mr. Posard holds a B.A. in Management Science from the University of San Diego.

Since 2013
Age 58
Tenure 13 yrs

Also at Halozyme Therapeutics, Inc.

HT Helen I. Torley President and Chief Executive Officer; Director JH Jeffrey W. Henderson Board Chair; Director BC Bernadette Connaughton Director BD Barbara Duncan Director MK Mahesh Krishnan Director JL James Lang Director

Roles

Organization Role Dates Details
Halozyme Therapeutics, Inc. Director 2013–present Current role
Explore DNA Founding Principal 2016-present Life sciences executive consulting firm.
GenePeeks, Inc. President and Chief Commercial Officer 2017-2018
Trovagene, Inc. Chief Commercial Officer 2015-2016
Illumina, Inc. Various commercial and general management positions, including VP Global Sales and SVP/GM of Clinical and Consumer Genomics and New and Emerging Markets 2006-2015 Part of the executive management team that led the company to its first $1 billion in revenue.
Illumina Commercial and general management positions (Global Sales, Marketing, GM) 2006-2015

External roles

Organization Role Dates
Nautilus Biotechnology, Inc. Chairman
Talis Biomedical Director (recent past public company board)
DermTech, Inc. Director (recent past public company board)
Nautilus Biotechnology Chairman 2021-
Stemson Therapeutics Executive Chairman 2019-

Related

Source: Halozyme Therapeutics, Inc. SEC filings and official company website

See how VectorShift works for your firm

Request Demo